TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Gout attacks (ACR/EULAR classification criteria 2015)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of type 2 diabetes mellitus (DM) after gestational diabetes mellitus (GDM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of participants with nausea
Endpoint domain: Adverse events/effects
Primary endpoint: Health-related Quality of Life (HRQoL) as assessed by Modified Total Illness Burden Index (TIBI-CaP)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HRQoL as assessed by SF-12v2 Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HRQoL as assessed by Functional Assessment of Cancer Therapy-Prostate (FACT-P)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: plasma F2-isoprostane response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NNS pressure waveforms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NNS-STI values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of recovery of platelet COX-1 activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immunological modifications of NK cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30-day Same Hospital Readmission Rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knee-specific quality of life score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Knee-specific activity score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of NV1FGF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of NV1FGF
Endpoint domain: Adverse events/effects
Primary endpoint: in vivo recovery of AT-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: half-life of AT-III
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical safety and tolerability of AT-III-DAF/DI
Endpoint domain: Adverse events/effects
Primary endpoint: Lowest dose of Rimonabant eliciting cannabis withdrawal
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemically-verified Abstinence From Smoking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leukemia response to SCRI-huCAR19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mean Change of HAI Serum Antibody Titers to A/California/07/09 (H1N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change of HAI Serum Antibody Titers to A/Michigan/45/2015 (H1N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change of HAI Serum Antibody Titers to A/Switzerland/9715293/13 (H3N2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change of MN Serum Antibody Titers to A/California/07/09 (H1N1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Perception of negative events following surgical procedures
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative subclinical DVT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Complete clearance of all lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Parkinson's Disease Questionnaire-39 (PDQ-39) Summary Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Wechsler Adult Intelligence Scale-IV (WAIS-IV) Matrix Reasoning Test total score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in State-Trait Anxiety Inventory (STAI) total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of cytotoxic T cells and regulatory T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in objective isokinetic abdominal strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histopathological Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postconcussive symptoms
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cardiac Energetic Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hb increase from baseline till day of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brain inflammation changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in syndemic conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in biological stress markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seroconversion from hepatitis B surface antigen positive to hepatitis B surface antibody positive
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patients' understanding of measurement tool items
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Usability of the technology interface for collecting PRO data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Radiological response to neoadjuvant chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Removal of free and esterified cholesterol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reactive hyperemia-peripheral artery tone index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: complete pathological remission rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transgastric sensor site healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Asthma symptoms measured by the Asthma Control Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Spirometric values (FEV1, FEV1/FVC, FEF25-75%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Bioavailability parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expansion of regulatory T cell compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Normalization of serum creatinine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Clinically significant hematoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average device pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average self-report pain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attrition (withdrawal) rate
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Gamma activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brain Metabolism measured via FDG-PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Focal oscillatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Agitation and sedation level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systemic therapy-free survival
Endpoint domain: Mortality/survival
Primary endpoint: proportion of patients experiencing grade 3 or higher toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Evaluation of Barrett's esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of flexor hallucis longus tears
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients Reaching ≥ 1log10 Decline of Quantitative HBsAg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Patterns of ACL injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Completion of Radiation Therapy and Vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation for Tumor Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Physical measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of bloodstream and catheter infection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe sepsis and septic shock
Endpoint domain: Adverse events/effects
Primary endpoint: Time of onset of effect of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Success or failure of the intrathecal block
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of Vi-TCV
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Epidermal Skin Loss at the Primary Site Assessed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain Scores at the Primary Site Assessed
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Urine cAMP Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Urine Osmolality (UOsm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful procedures performed by Hybrid EBUS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Ventilatory efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AUC Change in Level of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time of Death
Endpoint domain: Mortality/survival
Primary endpoint: Color Match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Sensitivity
Endpoint domain: Adverse events/effects
Primary endpoint: Gardos Channel Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Corpuscular Hemoglobin Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in the Number of Heavy Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Randomized Patients Who Are Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients in the Dinutuximab Arm Who Are Responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain feeling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: No need for more analgesics
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Cognitive state evaluated through Mini-Mental State Examination
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive performance evaluated through Montreal Cognitive Assessment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: The radiologic response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac Glucose Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of solicited adverse events after the first injection
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of serious adverse events or new chronic medical conditions through 24 weeks after the 2nd injection
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with seroconversion for each of the 2012/13 influenza vaccine strains (Group 1 and Group 2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Maintenance time of sensory and motor nerve block
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: length of oral lichen planus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: height of oral lichen planus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of plaque burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cell-mediated immunity response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in number of investigational tobacco products smoked per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IR (Infection Rate)
Endpoint domain: Adverse events/effects
Primary endpoint: Context effects of question order
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Intraoperative fentanyl needs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who achieve clinical remission as measured by PMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who achieve PUCAI response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who achieve clinical response as measured by Partial Mayo Score (PMS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of subjects who achieve Pediatric Ulcerative Colitis Activity Index (PUCAI) remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prematurity rate
Endpoint domain: Mortality/survival
Primary endpoint: Composite of Cardiovascular events
Endpoint domain: Mortality/survival
Primary endpoint: Hand pain on movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Presence of newly developed DWI lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Dietary Quality Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of good quality tumor samples obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: hemodynamic impact during laryngoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of active phase labour
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurological assessment using the LINCL clinical rating scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Patients With Grade 3-5 Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients Achieving Morphological Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sleep/wake activity
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Proportion of patients in complete response (CR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perioperative stroke
Endpoint domain: Mortality/survival
Primary endpoint: Cervical cytological results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometrial hyperplasia classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Recurring Distressing Dreams and Difficulty Falling and Staying Asleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Change in Sleep Assessed by the Pittsburgh Sleep Quality Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Severity of pain experienced by participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Netherton Area Severity Assessment score (NASA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of echo-endoscopic mediastinal staging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with postoperative pulmonary complication
Endpoint domain: Adverse events/effects
Primary endpoint: Intestinal toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Residual Gastric Volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Widespread Pain Index (WPI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tender Point Count (TPC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom Severity (SS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in aPTT (activated partial thromboplastin time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in PT (prothrombin time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants with New Atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of dendritic cells (DCs) in total white blood cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Concentration of sP-selectin (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement rate of venous insufficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Participants With Plasma HIV RNA < 200 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Alcohol, Illicit Substance and Cigarette Use During Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Relapse to Substance Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of inflammatory lesions compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change of inflammatory lesions compared to baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Overall tolerance of the treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Range of motion for distal interphalangeal joint extension lag
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decrease of LDL-C
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Survival with good neurological state
Endpoint domain: Mortality/survival
Primary endpoint: Area Under the Plasma Concentration-time Curve Over the Dosing Interval (AUC[0-24hours])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of uterus and myoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent penumbral salvage at 24-48h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pooled introduction or discontinuation of diuretics, antibiotics or anticoagulants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adjustment Disorder - New Module 20 (ADNM-20)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained Virologic Response 12 Weeks After Completion of Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ratio of warfarin PK parameters - AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of pancreatic tumor ablation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: MRI scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severe Hypoglycemic Events
Endpoint domain: Adverse events/effects
Primary endpoint: Expulsion rate of endometrial polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative axillary nodal status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lymphatic system outcomes
Primary endpoint: Number of Participants With On-Treatments Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Functional Vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Veterans RAND-12 Mental Component Score (VR-12 MCS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proinflammatory cytokines serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Wisconsin Card Sorting task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Probabilistic reversal learning task performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Pain after the process
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feeding Behavior Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Severity of pneumonia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes